As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’

As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’

Archived version: https://archive.is/newest/https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead

Disclaimer: The article linked is from a single source with a single perspective. Make sure to cross-check information against multiple sources to get a comprehensive view on the situation.

    • Tar_Alcaran
      5•3 days ago

      My last Jaxt adrenaline injector was 56 euros. An EpiPen would have been 2 whole euros extra.

  • Nougat
    12•3 days ago

    “Oh, we can’t do that. We have to make back R&D costs and turn a nice profit for like a decade before other companies are allowed to produce a generic version. We’re literally going to capitalize on human suffering. Suck it.”

    • @Bronstein_Tardigrade@lemmygrad.ml
      9•3 days ago

      Only a decade? Buy off some politicians and you’ll be able to milk profits for a century. Just look at the price gouging fiesta pharma has had with insulin.

  • DestideEnglish
    1•3 days ago

    We’ll just take this to India annnnd it’s $15